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Abstract
BK virus (BKV) associated nephropathy affects 1–10% of kidney transplant recipients, lead-
ing to graft failure in about 50% of cases. Immune responses against different BKV antigens
have been shown to have a prognostic value for disease development. Data currently sug-
gest that the structural antigens and regulatory antigens of BKV might each trigger a differ-
ent mode of action of the immune response. To study the influence of different modes of
action of the cellular immune response on BKV clearance dynamics, we have analysed the
kinetics of BKV plasma load and anti-BKV T cell response (Elispot) in six patients with BKV
associated nephropathy using ODE modelling. The results show that only a small number of
hypotheses on the mode of action are compatible with the empirical data. The hypothesis
with the highest empirical support is that structural antigens trigger blocking of virus produc-
tion from infected cells, whereas regulatory antigens trigger an acceleration of death of
infected cells. These differential modes of action could be important for our understanding
of BKV resolution, as according to the hypothesis, only regulatory antigens would trigger
a fast and continuous clearance of the viral load. Other hypotheses showed a lower degree
of empirical support, but could potentially explain the clearing mechanisms of individual
patients. Our results highlight the heterogeneity of the dynamics, including the delay
between immune response against structural versus regulatory antigens, and its relevance
for BKV clearance. Our modelling approach is the first that studies the process of BKV clear-
ance by bringing together viral and immune kinetics and can provide a framework for per-
sonalised hypotheses generation on the interrelations between cellular immunity and viral
dynamics.
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Author summary
BK virus (BKV) is the cause of a kidney disease affecting 1–10% of kidney transplant
recipients, which leads to transplantation failure in about 50% of the cases. This disease
is not well understood, but there are indications that markers of the immune response
against BKV can be used to predict the outcome. Since the immune response can act
through different modes of action, we have studied the dynamics between immune
response and virus to determine which modes of action play an important role in the fight
against BKV. We have analysed immune and viral kinetics in six kidney transplantation
patients and developed a mathematical model to integrate the data and better understand
the interactions between virus and immune response to different BKV antigens. Our
results allow for discarding the majority of action modes hypotheses. The most supported
hypothesis is: structural proteins trigger the blocking of virus production by infected cells,
whereas non-structural proteins trigger the acceleration of infected cells death. This differ-
ence could be central for disease outcome, as under this hypothesis only the latter would
trigger a fast and continuous BKV clearance.
Introduction
In the last years, BK virus-associated nephropathy (BKVN) has become the most challenging
infectious cause of renal graft dysfunction in kidney transplant, leading to graft failure in over
50% of cases [1,2]. The rise in BKVN incidence has been attributed, at least to some degree, to
the increased potency of immunosuppressive drugs [3,4]. Given the absence of specific antivi-
ral treatments, BKVN is handled by changing the immunosuppressive regimes of the patients,
enabling the development of a specific antiviral immune response [3–5]. Diagnosis of BKVN
is performed through renal biopsy [3,6–8] as progression of the illness occurs without clinical
signs, except for an increase in serum creatinine concentrations [1]. In the absence of medical
intervention, BKVN can cause extensive fibrosis and tubular atrophy in the allograft, leading
to transplant loss [1,3,7]. This progression is accompanied by a high BK virus (BKV) plasma
load. Therefore, screening of plasma BKV viral load is currently recommended for the moni-
toring of BKVN [8,9].
BKV is a non-enveloped virus with an icosahedral capsid and a small circular double-
stranded DNA genome (~5kb), which encodes for the early regulatory proteins: small tumor
antigen (st) and large tumor antigen (LT) (here collectively referred to as sLT antigens), the
late structural viral proteins 1–3 (VP1, VP2 and VP3) (here referred to as VP antigens) and the
agnoprotein [3,10]. Latent BKV infection is very common among the healthy population, with
a prevalence above 80% [3,11–13].
In spite of a high frequency of self-limited BKV reactivation in kidney transplant recipients
[12,14,15], only 1–10% [2] of transplant recipients do actually develop BKVN. To determine
the factors leading to BKVN, much emphasis has been placed on the immune reaction against
BKV antigens. sLT and VP antigens (but not the agnoprotein) have been demonstrated to elicit
a T cell response, as we previously showed in our studies [16–18]. Our data suggest that cellular
immune reaction has a prognostic value for BKVN evolution [16]. However, T cell response
can act through a number of mechanisms—killing of infected cells, blocking virus production
or infection, among others—which should have different impacts on viremia control.
Although our data [16] suggest that VP and sLT antigens trigger substantially different
immune responses, the experimental data alone do not allow to determine the relation
between antigens, immune mechanisms and clearance. Sophisticated instruments, such as
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mathematical models tailored for data analysis of this particular question, are required to for-
malise and analyse whether different antigens trigger different immune mechanisms and what
these modes of action are.
The most widely used method for modelling viral dynamics is ordinary differential equa-
tions (ODE). It has, for instance, helped elucidate the dynamics of HIV-1, hepatitis and
opportunistic viruses in transplant recipients [19]. It has also been used for the study of BKV,
simulating the dynamics of viral production, predicting cytopathic effects of the virus and
explaining the interactions between viral reactivation in tubular epithelial cells, urothelial cells,
viremia and viruria [20,21]. However, to our knowledge, no model exists that incorporates the
activation of the immune response with viral clearance dynamics.
Therefore, in this study we have retrospectively analysed the data of BKV plasma load kinet-
ics and T cell responses against BKV antigens in six patients with biopsy-proven BKVN [16].
The objective of the analysis was to determine the dominant modes of action of the observed
immune responses. For this, a tailor-made ODE model was generated, allowing for the forma-
lisation of different hypotheses on the dominant modes of action of the immune response
against BKVN.
To accomplish our goal, we pursued the following strategy: Firstly, we obtained a continu-
ous curve that fits the time course of the T cell response data (Elispot) for each patient and
antigen. Secondly, we designed an ODE model for the viral load clearance dynamics depen-
dent on the T cell response curves. This model uses the former curves as input and simulates
the dynamics of three variables: number of healthy cells, number of infected cells and BKV
viral load. It incorporates three mechanisms of the immune system in viral clearance, allowing
for the simulation of nine different hypotheses about dominant modes of action. Lastly, we
evaluated all hypotheses for their capacity to reproduce the viral clearance data. Our results
allowed for the discarding of most hypotheses and suggested that the anti-VP response induces
the blocking of virus production while anti-sLT responses induces killing of infected cells.
This difference in modes of action could be central for disease outcome, since only the sLT
responses would trigger a fast and continuous BKV clearance under this hypothesis. These
results could therefore have implications in the development of new immunotherapies against
BKVN.
Results
Patient characteristics and clinical data
The study involved six renal transplant patients analysed in our previous study [16]. These six
patients (called Patient A to F in the following) received renal transplants between 12/2004
and 05/2009 and developed severe BKV reactivation in follow-up. The patients were moni-
tored for BKV viral load by quantitative polymerase chain reaction (qPCR). Cellular adaptive
immune response against the BKV antigens (VP1, VP2, VP3, st and LT) was monitored by
Interferon gamma (IFN-γ) Enzyme-Linked ImmunoSpot (Elispot), measured in spot forming
units (SFU) per 106 peripheral blood mononuclear cells (PBMC). Elispot read-outs are known
to accurately quantify antigen-specific T cell responses for BKV [22].
All patients had biopsy-proven BKVN and were initially treated with a tacrolimus-based
immunosuppressive regimen. Tacrolimus is a calcineurin inhibitor. It inhibits T cell activation
but does not have cell-depleting effects [23]. It is associated with significantly higher incidence
of BKVN compared to cyclosporine A, a less potent calcineurin inhibitor [24]. Upon BKV
reactivation and diagnosis of BKVN, tacrolimus was replaced by cyclosporine A. This immu-
nosuppressant switch is a commonly used protocol against BKVN, as cyclosporine A is known
to allow the onset of a T cell response against BKV [16,25]. Patients were monitored for BKV
Differential T cell response and BK virus dynamics in renal transplantation
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 3 / 20
viral load during the complete evolution of the illness. The immune response was measured at
the latest from the point of immunosuppressant switch until BKV clearance (Fig 1).
Description of viral load and Elispot experimental data
We observed a considerable diversity in the times needed to reach viremia clearance for each
patient, ranging from 117 days after viremia onset for Patient F to 1744 days (~4 years) for
Patient A. However, some common patterns could be observed. The immune response came
generally in two waves, the first with an anti-VP immune response (red, pink and yellow lines
in Fig 1) and the second, targeted against sLT antigens (light and dark green). Importantly, the
immune response against VP was triggered for all but patient C within a relatively short span
of time (< 70 days) after immunosuppressant switch. On the other hand, immune response
against the sLT antigens was observed in only five patients. Again patient C did not show any
Fig 1. Viral load and immune response data of the patients. For each patient, the time course of viral load (black) and the Elispot read-out for each immunogenic
BKV antigen (coloured) are plotted. The change of immunosuppressant therapy is marked as a dashed blue line. This change in immunosuppressant therapy is
known to foster the development of an immune response against BKV. On the upper row the patients that had not cleared within 700 days after transplantation are
shown, while those that achieved clearance in a shorter time appear in the lower row. Please note the difference of time scales between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g001
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immune response against either sLT antigen. Based on the delay between the VP and the sLT
immune responses, patients could be grouped in two categories: Patients D, E and F showed a
short delay of approximately 30 days, while patients A and B showed a much longer delay of
over 180 days.
The triggering of cellular immune responses against the BKV antigens occurred after the
immunosuppressant switch. This immune response led to a progressive decrease of viral load
until viral clearance was achieved. This decreasing phase took place for hundreds of days on
most cases. In the five patients showing an anti-sLT immune response, the emergence of this
response was tied to a substantially faster viral load decrease. This strongly suggests that the
kind of immune response triggered by the sLT antigens is inherently different from the one
triggered by VP antigens.
Fitting of a model of the immune response against BKV to obtain
continuous curves describing the T cell response
With the goal of using the immune response data as an input for the viral load clearance
dynamics model, we developed a simple curve based on one or more logistic functions to
describe the experimentally observed T cell response. The use of logistic functions to describe
T cell dynamics of antigen specific populations was chosen due to their simplicity and capacity
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antia(t) is the T cell response for an antigen, where a represents the antigen that elicits the
response. For the definition of parameters see Table 1. We chose the activation time ta as a free
parameter because the T cell response may start at different points in time for every antigen.
As it is possible that an immune response presents multiple boosting episodes, we considered
the possibility that at a second time point ta2 the parameters of the curve are replaced by a sec-
ond set of parameters. We fitted this function to the BKV specific immune response against
each of the five antigens (VP1, VP2, VP3, st and LT).
t = 0 was defined at a day for which there are both Elispot and viral load data and the viral
load is maximum compared to all later measurements. This was defined as follows: Patient A,
day 1363 after transplantation; B, day 412; C, day 538; D, day 175; E, day 235; and F, day 530.
Simulations were performed until the time point viral load becomes undetectable or there are
no further Elispot measurements. This time point was chosen because we aim to model only
the clearance process. The objective function used for the fitting takes the form of vertical
Table 1. Immune function curve parameters.
Name Meaning Unit
ta Activation time of immune response Days
ra Immune response growth rate Days-1
maxantia Maximum immune response SFU  10−6 PBMC
deca Maximum response decay rate Days-1
Definition of the parameters of the immune function curve (Eq 1)
https://doi.org/10.1371/journal.pcbi.1005998.t001
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where yðt; aÞ is the experimental value of the Elispot read-out at time t for antigen a. y(t,a,p)
is the calculated Elispot read-out for a given parameter set p. N is the total number of measure-
ments and A is the number of screened antigens. The results of the parameter estimation are
shown in S1 Table and Fig 2. As depicted in Fig 2, Eq 1 was sufficient to reproduce the immune
response time courses of all six patients. For the immune response to the structural antigens of
Patient A, a time point ta2 with a second parameter set was employed to achieve a minimum
value for the objective function of (4.1610−2), instead of the minimum achieved for only one
parameter set (2.2410−1) (see S1 Fig).
In order to study the differences in the mechanisms of the immune responses against struc-
tural (VP1, VP2, VP3) and regulatory (st, LT) antigens, the results of the fitting were summarised
Fig 2. Fitting of immune response data. The calculated values for the immune response (lines) are plotted against the observed values (plus sign). Note the
difference of time scales between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g002
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in a VP function and a sLT function. These functions are employed in the model of BKV viral
load clearance as an input, to model the influence of each immune response against BKV.
VPðtÞ ¼ maxðantiVP1ðtÞ; antiVP2ðtÞ; antiVP3ðtÞÞ   1
sLTðtÞ ¼ maxðantistðtÞ; antiLTðtÞÞ   1 ð3Þ
The maximum value is taken under the assumption that the effects of the antigens are not
additive, but that there is some degree of saturation. The functions are subtracted by one unit
because 1 is the baseline value of the logistic curve antia(t).
Model of BKV viral load clearance in dependence on immune response
time course
The evolution of BKV viral load clearance was described using a modified version of a basic
model of viral dynamics [29], such that
d
dt




  d  C tð Þ   b  C tð Þ  V tð Þ  1   nðtÞð Þ
d
dt
I tð Þ ¼ b  C tð Þ  V tð Þ  1   nðtÞð Þ   d  k  I tð Þ  1þm  mðtÞð Þ
d
dt
V tð Þ ¼ p  I tð Þ  1   ðtÞð Þ   c  V tð Þ ð4Þ
This model contains three variables: number of healthy cells (C), number of infected cells
(I) and BKV viral load in copies mL-1 (V). Healthy cells proliferate at a rate proportional to g;
this rate is limited by maxc, which represents total number of cells (including both healthy and
infected). Healthy cells die at a rate d and are infected in presence of virus at a rate β. Infected
cells die at a rate d  k, where k is virus-associated cytopathicity. Viruses are produced by the
infected cells at a rate p and get cleared by the excretory system at a rate c. For a schematic
representation of the model, see Fig 3. For a further definition of the parameters, see Table 2.
The three model variables (C, I and V) depend on the T cell response curves as defined in
previous section. To study the mode of action of T cell responses, we consider that T cells can
act via three mechanisms: (1) virus production blockage (described by function ε(t)), (2) kill-
ing of the infected cells (described by function μ(t)) and (3) infection blockage (described by
function υ(t)). ε(t), μ(t) and υ(t) take the form of the sum of Hill functions, a standard form for
describing a saturating function, with a maximum value of 1, such that
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max þmaxE  1
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maxn þmaxN  1 ð5Þ
Fig 3. Schematic representation of the ODE model. Healthy cells produce other healthy cells (rate proportional to g) and die at rate d. The virus triggers
the conversion of healthy cells into infected cells (rate β). Infected cells die at rate dk and produce the virus at rate p, which is cleared at rate c. The immune
system can intervene through three different mechanisms: blocking virus production (ε(t)), enhancing infected cell death (μ(t)) and blocking infection
(ν(t)).
https://doi.org/10.1371/journal.pcbi.1005998.g003
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where ε(t), μ(t) and υ(t) depend on the VP(t) and the sLT(t) immune responses, as defined in
Eq 3.
Hypotheses on immune modes of action on the BKV viral load clearance
model
The objective of our work is to find the dominant modes of action responsible for viral load
clearance. Therefore, we assume for the model that each one of the two immune responses
(VP(t) and sLT(t)) acts through only one mode of action, either ε(t), μ(t) or υ(t) (Eq 5). As
these are three modes of action and two antigen-specific responses, nine different hypotheses
on the relationship between dominant modes of action and immune response are possible.
These nine hypotheses are referenced here following this convention: For example, the
hypothesis that anti-VP triggers a μ(t) response (accelerated killing) and anti-sLT triggers a
υ(t) response (infection blockage) is named VPμ-sLTυ hypothesis. For the definition and
description of all nine hypotheses, see S2 Table.
Testing of hypotheses for dominant modes of action of the immune system
in BKV clearance
To evaluate the feasibility of the hypotheses for dominant modes of action of the immune sys-
tem, the model was fitted against the BKV clearance data for all nine hypotheses. The parame-
ters c, g, d, β and p were estimated based on previous publications. Parameter k was estimated
for each hypothesis based on one particular patient, while the remainder of the parameters
were estimated individually for each patient and hypothesis.
The rate constant c for virus clearance was fixed to the value calculated by Funk et al. [30].
In the case of g, which is the maximum replication capacity for C(t) + I(t)<<maxc, cell culture
results show a maximum duplication rate of approximately one day for renal foetal kidney
cells [31]. Therefore, for the sake of simplicity we assigned a value of 1 days-1 for g. For the cell
death rate of healthy cells d, a value of 0.01 days-1 was used on a model of similar structure for
Hepatitis C virus [32] and it was deemed to be reasonable estimation here. The value of the
virus production rate p was calculated in the same model to be 100 copies mL-1  cells-1 
days-1 [32]. Given that BKV is a less aggressive infection, we deemed it reasonable to assume
a value of 15 copies mL-1 cells-1  days-1. This has the property that, for I(t) = V(t) and no
immune reaction, the viral load is in a steady state. Likewise, as the cell infection rate β for
the Hepatitis C virus was estimated to be 310−7 copies-1 mL  days-1 [32], a value of 310−8
copies-1 mL  days-1 for BKV was assumed. Patient C had the slowest progression of viral
Table 2. Viral load clearance model parameters.
Name Meaning Unit
g Self-regeneration of healthy cells rate Days-1
maxc Maximum number of total cells Cells
d Cell death independent of viral cytotoxicity rate Days-1
β Cell infection rate Copies-1 mL  days-1
k Viral cytopathicity factor Unitless
p Virus production rate Copies mL-1  cells-1  days -1
c Virus clearing rate Days-1
m Maximum value of accelerated killing with μ(t) Unitless
Definition of the parameters of the viral load clearance model (Eq 4)
https://doi.org/10.1371/journal.pcbi.1005998.t002
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clearance, which suggests that immune cytotoxic effects were relatively low. Therefore, we esti-
mated the viral cythopathic factor (k) for all patients using data obtained from Patient C. The








which takes the form of vertical least-squares. N is the total number of measurements, yðtÞ is
the viral load at the time t, y(t, p) is the simulated viral load for a parameter set p and time t.
The initial conditions for all cases were
For t = 0:
C 0ð Þ ¼ maxc  
c
p
 V 0ð Þ
I 0ð Þ ¼
c
p
 V 0ð Þ
Vð0Þ ¼ Vð0Þ ð7Þ
so that, at time t = 0 and no immune response, viral load is in steady state. V(0) is defined as
the observed viral load at t = 0. t = 0 was defined as above. The results obtained for the fittings,
as well as the model selection criterion (see Materials and methods) for each hypothesis and
patient, are shown in Table 3.
The results in Table 3 were interpreted to discard hypotheses based on the ΔBIC score and
the value of the objective function. Accordingly, there is good empirical support to generally
discard hypotheses VPν-sLTν and VPν-sLTε as probable mechanisms for viral clearance.
Table 3. Results of the model fitting for the hypotheses on dominant immune modes of action.
Patient Measurement VPε-sLTε VPε-sLTμ VPε-sLTν VPμ-sLTε VPμ-sLTμ VPμ-sLTν VPν-sLTε VPν-sLTμ VPν-sLTν
Number parameters 7 6 5 6 7 6 5 6 7
A f 0.11957 0.03090 0.06613 0.05490 0.04409 0.06091 0.14584 0.05053 1.88160
ΔBIC 11.4180 0.0000 3.3800 4.0233 4.4336 4.7510 8.9165 3.4425 30.7098
B f 0.06843 0.01120 0.06046 0.03153 0.02190 0.02233 0.06159 0.01994 0.06227
ΔBIC 14.6151 0.0000 9.8562 7.2449 6.6399 4.8297 9.9857 4.0387 13.9550
C f 0.01280 0.01030 0.01230 0.01070 0.01070 0.01070 0.01050 0.01050 0.01020
ΔBIC 5.6813 0.0000 2.48438 0.5334 3.1725 0.5334 0.2692 0.2692 2.5025
D f 0.00005 0.00044 0.10923 0.01080 0.18563 0.15925 0.01870 0.13048 2.33900
ΔBIC 0.0000 7.2157 27.9327 20.0636 32.8264 30.8273 20.8732 30.0301 42.9616
E f 0.17314 0.05591 0.25664 0.05083 0.08718 0.11018 3.03501 0.28754 2.40041
ΔBIC 11.8850 0.7632 10.8748 0.0000 6.3957 6.1895 30.6372 13.8637 32.9195
F f 1.25703 0.15598 1.31113 0.24925 0.21315 0.12060 1.31455 0.12063 4.25438
ΔBIC 10.7624 1.0289 8.1584 2.9039 3.6644 0.0000 8.1688 0.0008 15.6392
fSUM 1.63101 0.26472 1.81587 0.40800 0.56264 0.48397 4.58619 0.61961 10.94786
Median ΔBIC 11.0902 0.3816 9.0073 3.4636 5.4146 4.7903 9.4511 3.7406 23.1745
The results for the objective function f (Eq 6) and ΔBIC (Eqs 8 and 9) are shown for each one of the hypotheses and patients. The sum of the objective functions over all
patients is shown as fSUM. In bold are highlighted: The lowest per patient values for f, as well as the scores of ΔBIC within the range of substantial empirical support (<2).
The definitions of the hypotheses are shown in S2 Table. Detailed results of the model selection criteria are shown in S3 Table. S2 Fig shows the results of the fittings for
each hypothesis, compared to the best-performing hypothesis.
https://doi.org/10.1371/journal.pcbi.1005998.t003
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Hypotheses VPμ-sLTν, VPε-sLTν, VPε-sLTε, VPμ-sLTμ and VPν-sLTμ can only be consid-
ered as possible mechanisms for individual patients but not for the entire patient cohort.
Hypothesis VPμ-sLTε cannot be discarded but does not show the highest degree of empirical
support.
The hypothesis VPε-sLTμ has the lowest median ΔBIC and thus the highest empirical sup-
port. For five out of six patients, this hypothesis was within the range of substantial empirical
support (ΔBIC<2) [33], while no other hypothesis had comparable support for more than two
patients. This hypothesis associates an anti-VP response with virus production blockage and
an anti-sLT response with accelerated killing of infected cells. The hypothesis VPε-sLTμ is
shown compared to the other alternative hypotheses in S2 Fig.
Results of the parameter estimation, confidence intervals and the objective function for
the VPε-sLTμ hypothesis are shown in Table 4. The fitted model for each patient is shown on
Fig 4.
In spite of the good results of the fitting, the estimated values of the parameters should be
taken with caution. The results show heterogeneity between patients, especially maxc, hillε and
θε, with a range of around 3 orders of magnitude. This could be partly caused by parameter
uncertainty, as supported by the 95% confidence intervals, which for some parameters range
over 2 orders of magnitude. However, the variation of parameters between patients is larger
than the confidence intervals for each patient, confirming that the high variation is not solely a
Table 4. Parameter for the viral load clearance model under hypothesis VPε-sLTμ.
Patients
Parameter Type A B C D E F
g Fixed value 1.00
d Fixed value 1.0010−2
p Fixed value 15.00
β Fixed value 310−8
c Fixed value 15.00
k Fixed value 1.02
maxc Estimated value 5.52105 6.91105 3.39105 1.91108 3.78106 1.17107
95% Confidence
interval





m Estimated value 48.3 4.27 - 15.8 25.9 24.9
95% Confidence
interval
[47.3, 55.9] [4.21, 4.86] - [13.2, 18.5] [16.4, 41.6] [11.5, 86.5]













θε Estimated value 1.08102 1.16102 1.48102 3.1510−1 61.0 78.7
95% Confidence
interval




[5.93, 89.4] [3.0710−4, 1.68108]
hillμ Estimated value 1.30102 1.34102 - 98.6 1.36102 1.13102
95% Confidence
interval
[1.29102, 1.30102] [1.28102, 1.34102] - [47.5, 1.49102] [38.8, 1.74102] [19.5, 1.49102]
θμ Estimated value 2.04102 2.00102 - 22.7 87.3 2.10102
95% Confidence
interval
[2.03102, 2.04102] [1.99102, 2.00102] - [22.2, 29.2] [50.0, 1.19102] [1.37, 3.28102]
f Obj. Function 3.1010−2 1.1210−2 1.0310−2 4.4010−3 5.6010−2 1.5610−1
Results of the fitting for the viral clearance model (Eqs 3–5) under hypothesis VPε-sLTμ (S2 Table) for all six patients. The last row indicates the value of the objective
function (Eq 6).
https://doi.org/10.1371/journal.pcbi.1005998.t004
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product of parameter uncertainty. This is not surprising, as there is a very high degree of varia-
tion in the clearing time courses of the patients.
Note that the fitted parameters summarise complex biological processes, as opposed to
reflecting fundamental mechanisms, rendering it difficult to interpret parameter variations.
Nevertheless, fundamental biological variation between patients is conceivable. A clear case is
patient F. This patient had a simultaneous activation of the anti-VP and anti-sLT immune
response, and the extremely low estimate for hillε and very broad confidence intervals hillε and
θε, suggest that the anti-sLT immune response through the μ mode of action could have a satu-
rating effect over the anti-VP immune response. In fact, assuming only an anti-sLT response
for patient F led to an increase of f of less than 5% in comparison to the original VPε-sLTμ,
with substantially lower BIC values (see S3 Table). This result supports the possibility of a satu-
rating anti-sLT response for this patient.
Fig 4. Modelled time course of BKV viral load clearance for hypothesis VPε-sLTμ. The results of the model (Eqs 3–5) under hypothesis VPε-sLTμ (S2 Table)
using the parameters in Table 4 are plotted: viral load (V(t)) is shown as a black line, the immune responses virus production blockage (ε(t)) and accelerated killing
of infected cells (μ(t)) are shown in green and red, respectively. Observed viral load values are shown as black plus signs. Please note the difference of time scales
between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g004
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Sensitivity analysis of the model
To analyse the impact of the chosen values for the fixed parameters g, d, p, β and k on the
behaviour of the model, a sensitivity analysis was performed. The goal was to analyse whether
the same quality of fitting and qualitative behaviour of the model can be achieved for different
values of these parameters. The analysis was performed following the principle of one-factor-
at-a-time. The value of a single parameter was modified over a span ranging from a factor 0.1
of the original value up to 10; for each new value of the parameter a fitting was performed to
minimise the value of the objective function (Eq 6). The detailed results of the sensitivity analy-
sis are shown in S4 Table, the results for the extreme values (factors 0.1. and 10) are plotted in
S3 Fig.
Briefly, the results show that the model VPε-sLTμ can robustly simulate the viral clearance
dynamics of the six patients and is not sensitive to variations of the fixed parameters: For the
extreme values (factors 0.1 and 10), fittings with fSUM < 0.4 were achieved in all cases. This is
especially relevant when comparing the results with those for the mode of action hypotheses
(Table 3), where the best alternative hypothesis had a fSUM = 0.40800. Taken together, the
results of the analysis reinforce the relevance of the hypothesis VPε-sLTμ, demonstrating that
it is able to fit the viral dynamics better than the other hypotheses, even when modifying the
fixed parameters across two orders of magnitude.
Discussion
In this work we have created the first model that provides evidence of the dominant modes of
action involved in the clearance of BKV. It is the first model that covers the process of BKV
clearance harmonising the viral and immune dynamics and formalising different modes of
action of the immune system and their influence on the viral dynamics. It incorporates the
influence of the adaptive immune system on the clearance of BKV reactivation in a patient-to-
patient basis by considering multiple antigens and immune reactions against the same viral
infection and highlighting certain patterns of the process of immunological re-arming against
BKV after immunosuppressant switch. Our results show that immune modes of action can be
captured by acquisition of time series of blood markers not directly related to mechanistic
observations. Taken together, our work can be used as a tool for personalised hypothesis gen-
eration and evaluation of the modes of action through which the immune system successfully
fights against BKVN.
Our model suggests that for VP-specific cellular immune response, the dominant mode of
action is reducing the rate of virus production, while the mode of action triggered by sLT-anti-
gen specific T cells is an increased death rate of infected cells. This remarkable feature would
be central for BKV clearance: the VP-triggered immune response would cause an initial drop
in the viral load, leading to a plateau, where reduction of the viral load is slower than 0.5
log10(virusmL
-1) every 100 days. Only the acceleration of death of infected cells, triggered by
the sLT antigens, would lead to a fast and continuous clearance of the viral load. It further sug-
gests that in cases of simultaneous anti-VP and anti-sLT response, the latter response would
play the central role in viral clearing.
This hypothesis, VPε-sLTμ, achieved substantial empirical support for five out of six
patients, while none of the alternative hypotheses on dominant modes of action had substan-
tial empirical support for more than two patients. Even though one alternative hypothesis
could be used to fit the viral dynamics of the patients satisfactorily, the VPε-sLTμ hypothesis
achieved the lowest total value for the objective function.
The suggested VP-triggered blockage of virus production can be linked mechanistically to
the action of some cytokines, such as type I-interferons; while sLT-triggered accelerated
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killing can be associated with cytotoxic cells. This qualitatively different role of both antigen
groups is in agreement with biological evidence provided by a previous flow cytometry-
based study on VP1- and LT-specific CD4+ and CD8+ T-cells in patients with BKV reactiva-
tion [34]. In this work, VP1 elicited a significantly higher response in CD4+ T-cells than in
CD8+ T-cells. In the case of the LT antigen, even though there was no significant difference
between the magnitude of the CD4+ and the CD8+ T-cell responses, CD8+ cells were signifi-
cantly more likely to respond against LT than VP1. The agreement between the hypothesis
with the highest empirical support and the cited study highlights, in our opinion, the capabil-
ities of using our model as an instrument for hypothesis generation on the physiological
background of BKV clearance.
Interestingly, our model highlights a feature of heterogeneity among patients, the delay
between anti-VP and anti-sLT immune response, as central for BKV dynamics, linking it to
the previously presented division of patients into two groups—with a first group (upper row in
Fig 4) clearing the infection after over 300 days and a second group (lower row) clearing the
infection in around 100 days after immunosuppressant switch—in terms of an increased clear-
ance speed associated with anti-sLT immune response. Our model highlights the close rela-
tionship between viral clearance and this delay, underscoring that anti-sLT specific T cells are
needed for clearance. A delay between VP and sLT responses has been observed in two previ-
ous studies [16,34]. However, in spite of having been observed repeatedly, there is to our
knowledge at present no discussion in the literature on this striking factor. Possible causes
could be related to the different ways of VP and sLT antigen presentation or to the effects of
immunosuppression. Based on the results of our model, we would welcome more profound
experimental and theoretical research on the reasons underlying the delay.
Moreover, our results suggest that heterogeneity is not confined to the delay between
immune responses but is a central feature of the BKV clearing dynamics: For certain individ-
ual patients, hypotheses other than VPε-sLTμ might be specifically suitable to explain their
viral clearance dynamics. There is also a high degree of variation in the estimated values of the
parameters between individuals for each hypothesis. A part of this variation may stem from
physiological differences. For example, in the case of patient F, for whom particularly extreme
values for some parameters were found, this can be linked to this patient being the only one
with simultaneous activation of anti-VP and anti-sLT immune responses: Analyses suggested
that the latter response could have a saturating effect, rendering the former irrelevant for the
viral dynamics.
A relevant aspect of the model is that the dynamics of the immune response and their
dependence on viral load were not explicitly modelled. The influence of the immune response
on viral load is taken into account but the hypothetical contribution of BKV viral load to the
building of an immune reaction is not addressed. This approach was chosen due to the high
complexity and heterogeneity of the dynamics of immune reaction after immunosuppressant
switch—especially the VP-sLT delay. Given that the mechanisms underlying this delay are cur-
rently unknown, we consider it to be highly unlikely that using currently available knowledge
the immune response can be predicted from viral load.
The findings of our work on immune modes of action are especially relevant for future
immunotherapeutic approaches against BKVN, since they suggest that the immune response
against regulatory sLT antigens is central for BKV clearance. The use of T cells specific for
BKV regulatory antigens is an interesting clinical approach, which has recently been shown to
be technically possible [35]. In this study, the authors established a protocol for the ex-vivo
generation of T cells specific for the antigens VP1 and LT, offering evidence of the specificity
and safety of these cells [35].
Differential T cell response and BK virus dynamics in renal transplantation
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 14 / 20
Our BKV clearance modelling approach provides a framework for the hypothesis genera-
tion on the interrelations between cellular immunity and viral load at a personalised basis. Fur-
ther research with the model could help us to improve therapeutic approaches in patients with
BKVN, with the final aim of preventing kidney graft failure. The results of our model strongly
suggest a general association between different target antigens and distinct mechanisms of the
cellular immune system, linking structural VP antigens with the blockage of viral production
and regulatory sLT antigens with cytotoxic effects. It further highlights the essential role of
anti-sLT antigen response in clearance. These results should serve as a stimulus for further
research on the differences between anti-VP and anti-sLT responses, particularly on their
mechanisms, exploring possible physiological differences between patients in this respect. A
suggested method could involve complementing the Elispot analysis with flow cytometry anal-
ysis of different cell populations reacting to each antigen (e.g. CD4+, CD8+, T helper 17, T reg-
ulatory) at all time points of the clearance process, with a special emphasis on the differences
between the early- and late-stage responses. The knowledge gained through these experiments,
as well as further implementations of our model, could open the door to the use of immuno-
therapy in the treatment, and perhaps prevention, of BKVN. Modelling approaches built upon
our work could then be used in a personalised basis to tailor the therapy according to the char-
acteristics of their viral and immune dynamics.
Materials and methods
Ethics statement
This study was approved by our local ethical review committee in compliance with the declara-
tion of Helsinki. Informed consent was obtained from all patients (Ethic Committee Charité
University Medicine, Berlin, Germany, 126/2001, 07/30/2001).
Monitoring of BKVN patients
Patients were monitored for serum BKV viral load from 4/2006 to 9/2012 and for BKV specific
immune response against VP and sLT from 01/2008 to 07/2010 as described in our previous
study [16]. Screening for viral load was performed monthly over the first six months after
kidney transplantation, then every three months, and again monthly during active BKV reacti-
vation, while screening for specific immune response with Elispot was performed monthly
since approximately the change of immunosuppressive therapy, until BKV clearance (<3000
copiesmL-1). A total of 167 viral load samples and 98 Elispot samples were collected. BKVN
was confirmed by histological examination of the graft biopsy.
Screening of BKV viral load
BKV viral load was measured by qPCR as described previously [15]. Briefly, BKV viral load
was measured with TaqMan Real Time PCR. DNA was isolated from serum using a QIAamp
DNA Mini Kit (Qiagen Corp., Hilden, Germany) according to the instructions of the manu-
facturer. PCR was performed with the TaqMan platform (ABI). PCR amplifications were set
up in a reaction volume of 25 u/μL using primer and probe at final concentrations of 900 nM
and 5 μM, respectively, amplifying the VP1 region of BKV. A plasmid standard containing the
VP1 coding region of respective virus was used to determine the copy number per millilitre.
Thermal cycling was begun with an initial denaturation step at 95˚C for 10 min that was fol-
lowed by 40 cycles at 95˚C for 15 s and 60˚C for 1 min.
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Screening of anti-BKV immune reaction
BKV-specific T cell immune response was determined by IFN-γ Elispot upon stimulation of
PBMC with 5 different BKV proteins (VP1, VP2, VP3, st and LT) as described in our previ-
ous study [16]. Briefly, PBMC were isolated from 10–20 mL of heparinised blood using the
standard Ficoll Hypaque density gradient centrifugation technique. For the Elispot assay,
96-well multiscreen filter plates (MAIPS 4510, Millipore, Billerica, MA, USA) were coated
with 100 μL of primary IFN-γ monoclonal antibody (mAb) at a concentration of 3 μg/mL
(IFNG M700A, Endogen, Woburn, MA, USA) and incubated overnight at 4˚C. A standard-
ised responder T-cell number of 2.5 × 105 PBMC per well was added in quadruple or at least
triplicate wells with one of the five stimulating peptides (1 μg/mL). Staphylococcus entero-
toxin B (SEB; Sigma, Munich, Germany, 1 μg/mL) was used as positive control and negative
controls were run in parallel using responder cells plus medium alone. Probes were incu-
bated for 24 hours at 37˚C. The detection of IFN-γ took place after an overnight incubation
at 4˚C with 100 μL (1 μL/mL) biotinylated detection IFN-γ antibody (IFNG-M701-B Biotin,
Endogen). After adding streptavidine (1 μg/mL) for 2 hours at room temperature, spots were
developed by adding 200μL visualization solution, AEC (3-amino-9-ethylcarbazole, Sigma)
in acetate buffer supplemented with H2O2 30% for 3–5 min. Resulting spots were counted
using a computer-assisted Elispot reader (Immunospot, Cellular Technologies, Ltd., Cleve-
land, OH, USA). The number of SFU10−6 PBMC was calculated by adding spot counts from
each well.
Parameter estimation of the mathematical models
The models were fitted using the function fminsearch of the mathematical open-access soft-
ware Scilab, which employs the Nelder-Mead algorithm [36]. To ensure that the minimum
of the objective function is reached, several replications (> 100) of the estimation were per-
formed, using vastly different (> 2 orders of magnitude in some cases) starting parameter sets.
The objective functions for the immune dynamics and the viral dynamics, which take the form
of vertical least-squares, are defined in the Results section (Eqs 2 and 7).
To avoid overestimating the degrees of freedom of each hypothesis, parameters appearing
only as the product of two free parameters are considered as only one free parameter. This is
the case for model VPμ-sLTμ, where mmaxμ and mmaxM are estimated as two parameters,
instead of three parameters.
Model selection
Bayesian Information Criterion (BIC) differences were employed as the model selection crite-
rion. Additionally, the Akaike’s Information Criterion (AIC) was also calculated. The cor-
rected Akaike’s Information Criterion (AICc) was not used, as its value was not calculable for
certain patient/hypotheses combinations. BIC and AIC were estimated for each patient i and
hypothesis h under the assumption of independent, normally distributed errors
BICih ¼ Ni ln fih þ Kih ln Ni
AICih ¼ Ni ln fih þ 2Kih ð8Þ
where Ni is the total number of measurements per patient i, Kih is the number of parameters
for patient i and hypothesis h, and fih is the objective function for patient i and hypothesis h as
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defined in Eq 6. [33] AIC and BIC differences were calculated as
DBICih ¼ BICih   minðBICi Þ
DAICih ¼ AICih   minðAICi Þ ð9Þ
where the function min denotes the lowest AIC or BIC achieved for a patient. A difference in
the range [0, 2] for ΔBICih is considered to give substantial empirical support for the hypothesis
h in patient i [33].
Estimation of 95% confidence intervals
95% confidence intervals were estimated using bootstrapping, as described in Banks et al. [37].
Briefly, for each of the six patients the dynamics were simulated with the best-performing
hypothesis (VPε-sLTμ) and the best-fitting parameter set (Table 4). Residuals for the viral
load were calculated as the difference between predicted and observed viral load for each time
point. The residuals of each patient (excluding the first residual, which is zero by definition)
were randomly resampled with replacement 1000 times, constructing 1000 artificial data sets
for each patient, each with the same number of measurements as the patient. These artificial
data sets were subject to fitting using as initial parameter values those in Table 4. The obtained
distribution of estimated parameters for each patient was employed to calculate the 95% confi-
dence intervals: for a normal distribution of parameter values for a patient, the confidence
intervals were calculated as the mean ± 1.96  standard deviation; for skewed distributions
(absolute value of skewness or kurtosis higher than 2), the 95% confidence intervals were cal-
culated directly from the 25th and 975-th entries in the set of ordered parameter estimates.
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S1 Table. Parameters for the immune function curve. Results of the fitting for the immune
response model in Eq 1 for all six patients and five antigens.
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S2 Table. Hypotheses on the dominant modes of action of the immune system as defined
by the model. Description of the possible hypotheses on the dominant modes of action of the
immune response against VP and sLT antigens, as defined by the model (Eqs 3–5).
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S3 Table. Detailed results for the model comparison criteria of the fittings for the nine
hypotheses. The results for patient F and hypothesis VPε-sLTμ are shown additionally under
the special assumption of a saturating sLT response.
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S4 Table. Results of the sensitivity analysis for the fixed parameters.
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S1 Fig. Comparison of anti-VP responses fittings for patient A. Results of the fitting assum-
ing only one activation event, compared to the fitting for two activation events.
(TIF)
S2 Fig. Comparison of the fittings of the hypotheses to the best-performing hypothesis.
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(PDF)
Author Contributions
Conceptualization: Arturo Blazquez-Navarro, Ulrik Stervbo, Edda Klipp, Avidan U. Neu-
mann, Michal Or-Guil.
Data curation: Arturo Blazquez-Navarro, Ulrik Stervbo, Avidan U. Neumann.
Formal analysis: Arturo Blazquez-Navarro.
Funding acquisition: Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Investigation: Thomas Schachtner, Anett Sefrin, Maik Stein, Timm H. Westhoff, Petra
Reinke, Nina Babel.
Methodology: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Project administration: Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Resources: Petra Reinke, Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Software: Arturo Blazquez-Navarro.
Supervision: Edda Klipp, Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Validation: Arturo Blazquez-Navarro.
Visualization: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Writing – original draft: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Writing – review & editing: Thomas Schachtner, Ulrik Stervbo, Anett Sefrin, Maik Stein,
Timm H. Westhoff, Petra Reinke, Edda Klipp, Nina Babel.
References
1. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropa-
thy: state of affairs. Transplantation. 2009; 87: 621–630. https://doi.org/10.1097/TP.
0b013e318197c17d PMID: 19295303
2. Comoli P, Binggeli S, Ginevri F, Hirsch HH. Polyomavirus-associated nephropathy: update on BK virus-
specific immunity. Transpl Infect Dis. 2006; 8: 86–94. https://doi.org/10.1111/j.1399-3062.2006.00167.
x PMID: 16734631
3. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003; 3: 611–623. PMID: 14522260
4. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis. 2005; 41: 354–360. https://doi.org/
10.1086/431488 PMID: 16007533
5. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti
Infect Ther. 2007; 5: 105–115. https://doi.org/10.1586/14787210.5.1.105 PMID: 17266458
6. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by
needle biopsy. Am J Kidney Dis. 1995; 26: 671–3. PMID: 7573026
7. Trofe J, Gordon J, Roy-Chaudhury P, Koralnik IJ, Atwood WJ, Alloway RR, et al. Polyomavirus
nephropathy in kidney transplantation. Prog Transplant. 2004; 14: 130–140. PMID: 15264457
8. Nickeleit V, Singh HK, Mihatsch MJ. Polyomavirus nephropathy: morphology, pathophysiology, and
clinical management. Curr Opin Nephrol Hypertens. 2003; 12: 599–605. PMID: 14564196
9. Bennett WM, Meyer L, Ridenour J, Batiuk TD. Surveillance and modification of immunosuppression
minimizes BK virus nephropathy. Am J Nephrol. 2010; 32: 10–2. https://doi.org/10.1159/000313888
PMID: 20484894
10. Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus—immune system
interplay. Nat Rev Nephrol. 2011 May 24; 7(7): 399–406. https://doi.org/10.1038/nrneph.2011.59
Differential T cell response and BK virus dynamics in renal transplantation
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 18 / 20
11. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of Polyomavirus BK and
JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis. 2009; 199: 837–846. https://doi.
org/10.1086/597126 PMID: 19434930
12. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of
polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;
347.
13. Egli A, Binggeli S, Bodaghi S, Dumoulin A, Funk GA, Khanna N, et al. Cytomegalovirus and polyomavi-
rus BK posttransplant. Nephrol Dial Transplant. 2007; 22: viii72–viii82. https://doi.org/10.1093/ndt/
gfm648 PMID: 17890268
14. Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in
de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized,
multicenter study. Am J Transplant. 2013; 13: 136–145. https://doi.org/10.1111/j.1600-6143.2012.
04320.x PMID: 23137180
15. Babel N, Fendt J, Karaivanov S, Bold G, Arnold S, Sefrin A, et al. Sustained BK viruria as an early
marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum sam-
ples. Transplantation. 2009; 88: 89–95. https://doi.org/10.1097/TP.0b013e3181aa8f62 PMID:
19584686
16. Schachtner T, Müller K, Stein M, Diezemann C, Sefrin A, Babel N, et al. BK virus-specific immunity
kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant.
2011; 11: 2443–52. https://doi.org/10.1111/j.1600-6143.2011.03693.x PMID: 21831150
17. Trydzenskaya H, Sattler A, Müller K, Schachtner T, Dang-Heine C, Friedrich P, et al. Novel approach
for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immu-
nity. Transplantation. 2011; 92: 1269–77. https://doi.org/10.1097/TP.0b013e318234e0e5 PMID:
22124284
18. Mueller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, et al. BK-VP3 as a New Tar-
get of Cellular Immunity in BK Virus Infection. Transplantation. 2011; 91: 100–107. https://doi.org/10.
1097/TP.0b013e3181fe1335 PMID: 21452414
19. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol. 2002 Jan; 2(1): 28–36.
20. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH. Polyomavirus BK replication dynamics in vivo and
in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant. 2008; 8:
2368–77. https://doi.org/10.1111/j.1600-6143.2008.02402.x PMID: 18925904
21. Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients.
J Infect Dis. 2006; 193: 80–87. https://doi.org/10.1086/498530 PMID: 16323135
22. Chakera A, Bennett S, Lawrence S, Morteau O, Mason PD, O’Callaghan CA, et al. Antigen-specific T
cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide
immunosuppression following renal transplantation. Clin Exp Immunol. 2011; 165: 401–409. https://doi.
org/10.1111/j.1365-2249.2011.04429.x PMID: 21671906
23. Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016; 11: 332–343. https://doi.
org/10.2215/CJN.08570814 PMID: 26170177
24. Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, et al. The risk of polyomavirus-associ-
ated graft nephropathy is increased by a combined suppression of cd8 and cd4 cell-dependent immune
effects. Transplant Proc. Elsevier Inc.; 2013; 45: 1608–1610. https://doi.org/10.1016/j.transproceed.
2013.01.026 PMID: 23726630
25. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of Polyomavirus Infec-
tion in Kidney Transplant Recipients: A Systematic Review. Transplantation. 2010; 89: 1057–1070.
https://doi.org/10.1097/TP.0b013e3181d0e15e PMID: 20090569
26. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: Potential treatment
strategies evaluated in a mathematical model. Cancer Res. 2006; 66: 7293–7300. https://doi.org/10.
1158/0008-5472.CAN-06-0241 PMID: 16849579
27. Perelson AS, Nelson PW. Mathematical Analysis of HIV-1 Dynamics in Vivo. SIAM Rev. 1999; 41: 3–
44. https://doi.org/10.1137/S0036144598335107
28. Huang Y, Rosenkranz SL, Wu H. Modeling HIV dynamics and antiviral response with consideration of
time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 2003; 184: 165–186.
https://doi.org/10.1016/S0025-5564(03)00058-0 PMID: 12832146
29. Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. BioEssays. 2002; 24:
1178–1187. https://doi.org/10.1002/bies.10196 PMID: 12447982
30. Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients.
J Infect Dis. 2006; 193: 80–87. https://doi.org/10.1086/498530 PMID: 16323135
Differential T cell response and BK virus dynamics in renal transplantation
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 19 / 20
31. Kim S-S, Gwak S-J, Han J, Park MH, Song KW, Kim B-S. Regeneration of kidney tissue using in vitro
cultured fetal kidney cells. Exp Mol Med. 2008; 40: 361–369. https://doi.org/10.3858/emm.2008.40.4.
361 PMID: 18779648
32. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in
vivo and the antiviral efficacy of interferon-therapy. Science (80-). 1998; 282: 103. https://doi.org/10.
1126/science.282.5386.103
33. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theo-
retic Approach (2nd ed). Ecological Modelling. 2002. https://doi.org/10.1016/j.ecolmodel.2003.11.004
34. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, et al. Polyomavirus BK-specific cellular immune
response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant. 2007; 7: 1131–9.
https://doi.org/10.1111/j.1600-6143.2007.01754.x PMID: 17359507
35. Lamarche C, Orio J, Georges-Tobar V, Pincez T, Goupil M, Dahmani A, et al. Clinical-scale Rapid
Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Vire-
mia for Adoptive Immunotherapy. Transplantation. 2017. https://doi.org/10.1097/TP.
0000000000001698 PMID: 28230645
36. Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965; 7: 308–313.
37. Banks HT, Baraldi R, Cross K, Flores K, McChesney C, Poag L, et al. Uncertainty quantification in
modeling HIV viral mechanics. Math Biosci Eng. 2015; 12: 937–964. https://doi.org/10.3934/mbe.2015.
12.937 PMID: 26280189
Differential T cell response and BK virus dynamics in renal transplantation
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 20 / 20
